JP2003517846A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003517846A5 JP2003517846A5 JP2001547141A JP2001547141A JP2003517846A5 JP 2003517846 A5 JP2003517846 A5 JP 2003517846A5 JP 2001547141 A JP2001547141 A JP 2001547141A JP 2001547141 A JP2001547141 A JP 2001547141A JP 2003517846 A5 JP2003517846 A5 JP 2003517846A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- subunit
- amino acid
- seq
- soluble receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 21
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 125000002228 disulfide group Chemical group 0.000 description 4
- 102000018358 Immunoglobulins Human genes 0.000 description 3
- 108060003951 Immunoglobulins Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 102100017908 IL20RA Human genes 0.000 description 1
- 101710029788 IL20RA Proteins 0.000 description 1
- 102100017907 IL20RB Human genes 0.000 description 1
- 101710029784 IL20RB Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010001618 interleukin-20 receptor Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 IL−20Aサブユニットが配列番号12、38、55、63、および65から成る群から選択されるアミノ酸配列を有するポリペプチドから構成され、そしてIL−20Bサブユニットが配列番号15、59、61、67、68、および69から成る群から選択されるアミノ酸配列を有するポリペプチドから構成されている、IL−20RAサブユニットおよびIL−20RBサブユニットから構成された単離された可溶性レセプター。
【請求項２】 前記IL−20AサブユニットおよびIL−20Bサブユニットがポリペプチドリンカーにより一緒に結合されている、請求項1に記載の可溶性レセプター。
【請求項３】 前記ポリペプチドリンカーが約100〜240アミノ酸残基を有する、請求項2に記載の可溶性レセプター。
【請求項４】 前記ポリペプチドリンカーが約170アミノ酸残基を有する、請求項3に記載の可溶性レセプター。
【請求項５】 前記IL−20AサブユニットおよびIL−20Bサブユニットの各々が該サブユニットに融合されたポリペプチドリンカーを有し、かつポリペプチドリンカーの各々が少なくとも1つのシステイン残基を有し、そしてIL−20AサブユニットのポリペプチドリンカーからのシステインとIL−20Bサブユニットのポリペプチドリンカーからのシステインとから少なくとも1つのジサルファイド結合を形成している、請求項1に記載の可溶性レセプター。
【請求項６】 前記IL−20Aサブユニットが免疫グロブリン（Ig）分子の重鎖の定常領域のすべてまたは一部分に融合されており、そして前記IL−20Bサブユニットが免疫グロブリン分子の軽鎖の定常領域のすべてまたは一部分に融合されており、それら軽鎖および重鎖が一緒にジサルファイド結合されている、請求項5に記載の可溶性レセプター。
【請求項７】 前記重鎖の定常領域がCH1ドメイン、CH2ドメイン、およびCH1ドメインをCH2ドメインに接続するヒンジ配列から構成されている、請求項6に記載の可溶性レセプター。
【請求項８】 前記重鎖の定常領域に融合されたIL−20Aサブユニットが配列番号23、53、54および62から成る群から選択されるアミノ酸配列から構成され、そして前記IgGの軽鎖の定常領域に融合されたIL−20Bサブユニットが配列番号21、57、58および60から成る群から選択されるアミノ酸配列から構成されている、請求項6に記載の可溶性レセプター。
【請求項９】 前記IL−20BサブユニットがIg分子の重鎖の定常領域のすべてまたは一部分に融合されており、そして前記IL−20Aサブユニットが免疫グロブリン分子の軽鎖の定常領域のすべてまたは一部分に融合されており、それら軽鎖および重鎖が一緒にジサルファイド結合されている、請求項5に記載の可溶性レセプター。
【請求項１０】 第1ポリペプチドが配列番号53および54から成る群から選択されるアミノ酸から構成されており、そして第2ポリペプチドが配列番号57および58から成る群から選択されるアミノ酸配列から構成されている、第2ポリペプチドに対してジサルファイド結合した第1ポリペプチドから構成されている可溶性IL−20レセプター。
【請求項１１】 第1ポリペプチドが配列番号23および62から成る群から選択されるアミノ酸から構成されており、そして第2ポリペプチドが配列番号21および60から成る群から選択されるアミノ酸配列から構成されている、第2ポリペプチドに対してジサルファイド結合した第1ポリペプチドから構成されている可溶性レセプター。
【請求項１２】 第1ポリペプチドが配列番号66のアミノ酸から構成されており、そして第2ポリペプチドが配列番号70および71から成る群から選択されるアミノ酸配列から構成されている、第1ポリペプチドおよび第2ポリペプチドを有するタンパク質。
[Claims]
1. The IL-20A subunit is composed of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 38, 55, 63, and 65, and the IL-20B subunit is SEQ ID NO: 15 , 59, 61, 67, 68, and 69, comprising a polypeptide having an amino acid sequence selected from the group consisting of: IL-20RA and IL-20RB subunits. Receptor.
2. The soluble receptor of claim 1, wherein said IL-20A and IL-20B subunits are joined together by a polypeptide linker.
3. The soluble receptor according to claim 2, wherein said polypeptide linker has about 100 to 240 amino acid residues.
4. The soluble receptor of claim 3, wherein said polypeptide linker has about 170 amino acid residues.
5. each of the IL-20A and IL-20B subunits has a polypeptide linker fused to the subunit, and each of the polypeptide linkers has at least one cysteine residue; 2. The soluble receptor according to claim 1, wherein the soluble receptor forms at least one disulfide bond from cysteine from the IL-20A subunit polypeptide linker and cysteine from the IL-20B subunit polypeptide linker.
6. The IL-20A subunit is fused to all or part of the constant region of the heavy chain of an immunoglobulin (Ig) molecule, and the IL-20B subunit is constant for the light chain of an immunoglobulin molecule. 6. The soluble receptor of claim 5, wherein the soluble receptor is fused to all or part of the region and the light and heavy chains are disulfide bonded together .
7. The soluble receptor according to claim 6, wherein the heavy chain constant region is composed of a CH1 domain, a CH2 domain, and a hinge sequence connecting the CH1 domain to the CH2 domain.
8. The IL-20A subunit fused to the heavy chain constant region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 23, 53, 54 and 62, and wherein the IgG light chain comprises 7. The soluble receptor according to claim 6, wherein the IL-20B subunit fused to the constant region is comprised of an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 57, 58 and 60.
9. The IL-20B subunit is fused to all or a portion of the heavy chain constant region of an Ig molecule, and the IL-20A subunit is all or part of the light chain constant region of an immunoglobulin molecule. 6. The soluble receptor of claim 5, wherein the soluble receptor is fused to a portion and the light and heavy chains are disulfide bonded together.
10. The method according to claim 10, wherein the first polypeptide is composed of an amino acid selected from the group consisting of SEQ ID NOs: 53 and 54, and the second polypeptide is composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 57 and 58. A soluble IL-20 receptor comprising a first polypeptide disulfide bonded to a second polypeptide.
11. The first polypeptide is composed of an amino acid selected from the group consisting of SEQ ID NOs: 23 and 62, and the second polypeptide is composed of an amino acid sequence selected from the group consisting of SEQ ID NOs: 21 and 60. A soluble receptor comprising a first polypeptide which is disulfide bonded to a second polypeptide.
12. The first polypeptide, wherein the first polypeptide is comprised of the amino acids of SEQ ID NO: 66 and the second polypeptide is comprised of an amino acid sequence selected from the group consisting of SEQ ID NOs: 70 and 71. A protein having a peptide and a second polypeptide.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47177499A | 1999-12-23 | 1999-12-23 | |
| US09/471,774 | 1999-12-23 | ||
| US21341600P | 2000-06-22 | 2000-06-22 | |
| US60/213,416 | 2000-06-22 | ||
| PCT/US2000/035307 WO2001046232A2 (en) | 1999-12-23 | 2000-12-22 | Soluble interleukin-20 receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003517846A JP2003517846A (en) | 2003-06-03 |
| JP2003517846A5 true JP2003517846A5 (en) | 2008-02-28 |
| JP4741139B2 JP4741139B2 (en) | 2011-08-03 |
Family
ID=26908064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001547141A Expired - Fee Related JP4741139B2 (en) | 1999-12-23 | 2000-12-22 | Soluble interleukin-20 receptor |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1246846B1 (en) |
| JP (1) | JP4741139B2 (en) |
| AT (2) | ATE407950T1 (en) |
| AU (1) | AU783473B2 (en) |
| CA (1) | CA2395539C (en) |
| DE (2) | DE60040240D1 (en) |
| DK (1) | DK1246846T3 (en) |
| RU (1) | RU2279441C2 (en) |
| UA (1) | UA84830C2 (en) |
| WO (1) | WO2001046232A2 (en) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2248828A1 (en) * | 1999-12-23 | 2010-11-10 | ZymoGenetics, Inc. | Method for treating inflammation |
| US7122632B2 (en) | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
| CA2395539C (en) | 1999-12-23 | 2009-08-25 | Zymogenetics, Inc. | Soluble interleukin-20 receptor |
| US6610286B2 (en) | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| US7045498B2 (en) | 2000-08-08 | 2006-05-16 | Zymogenetics, Inc. | Soluble Zcytor11 cytokine receptors |
| DE60141546D1 (en) | 2000-09-15 | 2010-04-22 | Zymogenetics Inc | Polypeptides containing the extracellular domain of IL-20RA and / or IL-20RB |
| CA2633171C (en) * | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
| AU2004223836A1 (en) | 2003-03-24 | 2004-10-07 | Zymogenetics, Inc. | Anti-IL-20 antibodies and binding partners and methods of using in inflammation |
| WO2005014028A1 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk A/S | Interleukin-20 for treating and diagnosing conditions associated with neovascularisation |
| BR122018071808B8 (en) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugate |
| BRPI0510883B8 (en) | 2004-06-01 | 2021-05-25 | Genentech Inc | drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination |
| RU2412947C2 (en) | 2004-09-23 | 2011-02-27 | Дженентек, Инк. | Antibodies, constructed on cysteine basis and their conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| CA2584157C (en) | 2004-10-22 | 2014-10-14 | Zymogenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
| AU2006212807A1 (en) | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| CA2652304A1 (en) * | 2006-05-17 | 2007-11-22 | Eberhard-Karls-Universitaet Tuebingen Universitaetsklinikum | Anti-inflammatory fusion protein |
| CN102281898B (en) * | 2008-10-07 | 2015-06-03 | 成功大学 | Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis |
| IN2012DN03025A (en) | 2009-09-09 | 2015-07-31 | Ct Se Llc | |
| JP2013520476A (en) | 2010-02-26 | 2013-06-06 | ノヴォ ノルディスク アー／エス | Stable antibody-containing composition |
| TWI540136B (en) | 2010-04-15 | 2016-07-01 | 梅迪繆思有限公司 | Pyrrolobenzodiazepines and conjugates thereof |
| US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
| SG185428A1 (en) | 2010-06-08 | 2012-12-28 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| JP5889912B2 (en) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | Alaninyl maytansinol antibody conjugate |
| JP5987053B2 (en) | 2011-05-12 | 2016-09-06 | ジェネンテック， インコーポレイテッド | Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides |
| CN103987407B (en) | 2011-10-14 | 2016-08-24 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepines Zhuo and conjugate thereof |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| DK2906296T3 (en) | 2012-10-12 | 2018-05-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| SI2906253T1 (en) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
| ES2680153T3 (en) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Anti-PSMA-pyrrolobenzodiazepine antibody conjugates |
| RS58921B1 (en) | 2012-10-12 | 2019-08-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| US9931414B2 (en) | 2012-10-12 | 2018-04-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| AU2013328628B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates |
| US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EP2935273A1 (en) | 2012-12-21 | 2015-10-28 | MedImmune Limited | Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases |
| KR102066318B1 (en) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | Pyrrolobenzodiazepines and conjugates thereof |
| EA027910B1 (en) | 2013-03-13 | 2017-09-29 | Медимьюн Лимитед | Pyrrolobenzodiazepines and conjugates thereof |
| MX362970B (en) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof. |
| WO2015023355A1 (en) | 2013-08-12 | 2015-02-19 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| US9956299B2 (en) | 2013-10-11 | 2018-05-01 | Medimmune Limited | Pyrrolobenzodiazepine—antibody conjugates |
| CA2929565A1 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| CR20160271A (en) | 2013-12-16 | 2016-12-02 | Genentech Inc | PEPTIDOMETIC COMPOUNDS AND THEIR ANTIBODY-DRUG CONJUGATES |
| WO2015095223A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| EP3151921B1 (en) | 2014-06-06 | 2019-08-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| CN106714844B (en) | 2014-09-12 | 2022-08-05 | 基因泰克公司 | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| JP2017533887A (en) | 2014-09-17 | 2017-11-16 | ジェネンテック， インコーポレイテッド | Pyrrolobenzodiazepines and their antibody disulfide conjugates |
| TWI758928B (en) | 2014-11-21 | 2022-03-21 | 美商必治妥美雅史谷比公司 | Antibodies against cd73 and uses thereof |
| HUE052526T2 (en) | 2014-11-21 | 2021-05-28 | Bristol Myers Squibb Co | Antibodies comprising modified heavy constant regions |
| BR112017011111A2 (en) | 2014-11-25 | 2017-12-26 | Adc Therapeutics Sa | pyrrolobenzodiazepine-antibody conjugates |
| EP3226909A1 (en) | 2014-12-03 | 2017-10-11 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| EP3304079B1 (en) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| MA43345A (en) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
| MA43354A (en) | 2015-10-16 | 2018-08-22 | Genentech Inc | CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE |
| MA45326A (en) | 2015-10-20 | 2018-08-29 | Genentech Inc | CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE |
| AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108700598A (en) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | The drug of the total antibody of multichannel and antibody conjugate quantifies measuring method |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| JP2019522633A (en) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | PROTAC antibody conjugates and methods of use |
| WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP7050770B2 (en) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Method for preparing antibody drug conjugate |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| US11160872B2 (en) | 2017-02-08 | 2021-11-02 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| JP2020517609A (en) | 2017-04-18 | 2020-06-18 | メディミューン リミテッド | Pyrrolobenzodiazepine complex |
| KR20190141666A (en) | 2017-04-20 | 2019-12-24 | 에이디씨 테라퓨틱스 에스에이 | Combination Therapy with Anti-AXL Antibody-Drug Conjugates |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
| MX2019015042A (en) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc. |
| CN111065638B (en) | 2017-08-18 | 2021-04-09 | 麦迪穆有限责任公司 | Pyrrolobenzodiazepine conjugates |
| BR112020004307A2 (en) | 2017-09-20 | 2020-11-10 | Ph Pharma Co., Ltd. | tailanestatin analogues |
| KR101933217B1 (en) * | 2017-12-28 | 2018-12-27 | (주) 에빅스젠 | Peptide for Inhibiting Skin Inflammation And Composition for Preventing or Treating Skin Inflammation Containing The Same |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| CN113056287A (en) | 2018-10-24 | 2021-06-29 | 豪夫迈·罗氏有限公司 | Conjugated chemical degradation inducers and methods of use |
| WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| CA2296762A1 (en) * | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
| HU227703B1 (en) | 1997-11-26 | 2011-12-28 | Zymogenetics Inc | Mammalian cytokine-like polypeptide-10 |
| ES2226335T3 (en) * | 1998-01-23 | 2005-03-16 | Immunex Corporation | RECEOOCTIRES OF UK.18. |
| AU2871899A (en) * | 1998-03-09 | 1999-09-27 | Schering Corporation | Human receptor proteins; related reagents and methods |
| ES2312205T3 (en) * | 1998-03-10 | 2009-02-16 | Genentech, Inc. | NEW POLYPEPTIDE AND NUCLEIC ACIDS THAT CODE IT. |
| AU5203199A (en) * | 1998-05-26 | 1999-12-13 | Procter & Gamble Company, The | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| AU4411699A (en) * | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Interferon receptor hkaef92 |
| WO2000039161A1 (en) * | 1998-12-31 | 2000-07-06 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
| JP2004522402A (en) * | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2395539C (en) * | 1999-12-23 | 2009-08-25 | Zymogenetics, Inc. | Soluble interleukin-20 receptor |
| EP2248828A1 (en) * | 1999-12-23 | 2010-11-10 | ZymoGenetics, Inc. | Method for treating inflammation |
-
2000
- 2000-12-22 CA CA002395539A patent/CA2395539C/en not_active Expired - Fee Related
- 2000-12-22 AU AU22925/01A patent/AU783473B2/en not_active Ceased
- 2000-12-22 WO PCT/US2000/035307 patent/WO2001046232A2/en active IP Right Grant
- 2000-12-22 DE DE60040240T patent/DE60040240D1/en not_active Expired - Lifetime
- 2000-12-22 RU RU2002119563/13A patent/RU2279441C2/en not_active IP Right Cessation
- 2000-12-22 AT AT00986743T patent/ATE407950T1/en active
- 2000-12-22 EP EP00986743A patent/EP1246846B1/en not_active Expired - Lifetime
- 2000-12-22 JP JP2001547141A patent/JP4741139B2/en not_active Expired - Fee Related
- 2000-12-22 DK DK00986743T patent/DK1246846T3/en active
- 2000-12-22 EP EP07012370A patent/EP1857466B1/en not_active Expired - Lifetime
- 2000-12-22 AT AT07012370T patent/ATE485306T1/en not_active IP Right Cessation
- 2000-12-22 DE DE60045139T patent/DE60045139D1/en not_active Expired - Lifetime
- 2000-12-22 UA UA2002075992A patent/UA84830C2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003517846A5 (en) | ||
| RU2002119563A (en) | INTERLEUKIN-20 SOLUBLE RECEPTOR | |
| JP2003507012A5 (en) | ||
| PL393286A1 (en) | Soluble BR43x2 receptor and methods for the application thereof | |
| JP2002536960A5 (en) | ||
| WO2002008293A3 (en) | Multivalent target binding protein | |
| JP2003522200A5 (en) | ||
| NZ596865A (en) | Single-chain multivalent binding proteins with effector function | |
| JP2003508350A5 (en) | ||
| JP2004523205A5 (en) | ||
| ATE223229T1 (en) | COMPOSITIONS OF CONJUGATES OF THE STABLE, ACTIVE, HUMAN OB PROTEIN WITH THE FC CHAIN OF IMMUNOGLOBULINS AND RELATED METHODS | |
| MÉRY et al. | Disulfide linkage to polyacrylic resin for automated Fmoc peptide synthesis. Immunochemical applications of peptide resins and mercaptoamide peptides | |
| WO2006101782A3 (en) | A cysteine-containing peptide tag for site-specific conjugation of proteins | |
| JP6598344B2 (en) | A super versatile method for presenting cyclic peptides in protein structures | |
| EA200000685A1 (en) | COMPLEX IFNAR2 / IFN | |
| WO2001081426A3 (en) | Rgd (arg-gly-asp) coupled to (neuro)peptides | |
| WO2003068977A3 (en) | Fusion constructs containing active sections of tnf ligands | |
| Sheridan et al. | Solid‐phase synthesis and cyclization of a large branched peptide from IgG Fc with affinity for FcγRI | |
| JP2000247999A (en) | Production of immobilized protein | |
| JP2007526919A5 (en) | ||
| JPWO2019211253A5 (en) | ||
| WO2001045745A3 (en) | A reversible linkage technology for controlled conjugation | |
| RU2000121342A (en) | GP120 HIV-1 PROTEIN EPITOP PEPTIDE SIMULATOR |